Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma

被引:55
作者
Ermetici, Federica
Malavazos, Alexis E.
Corbetta, Sabrina
Morricone, Lelio
Dall'Asta, Chiara
Corsi, Massimillano M.
Ambrosi, Bruno [1 ]
机构
[1] Univ Milan, Policlin San Donato, IRCCS, Endocrinol Unit,Dept Med & Surg Sci, I-20097 Milan, Italy
[2] Univ Milan, Inst Gen Pathol, Lab Clin Pathol, I-20133 Milan, Italy
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2007年 / 56卷 / 05期
关键词
D O I
10.1016/j.metabol.2006.12.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adrenal incidentalomas (AIs) have been associated with an increased incidence of several cardiovascular risk factors, similar to overt Cushing syndrome. Data about the involvement of the adipokines in the development of insulin resistance and atherosclerosis in AI are completely lacking. The aim of the present study was to evaluate plasma interleukin 6 (IL-6), adiponectin, resistin, tumor necrosis factor alpha TNF-alpha), and monocyte chemoattractant protein 1 (MCP-1) levels in patients with AI. Plasma IL-6, adiponectin, resistin, TNF-alpha. and MCP-1 levels were measured in 20 healthy subjects (6 males; 14 females; age, 58.5 +/- 2.2 years; body mass index, 28.1 +/- 0.9 kg/m(2)) and in 20 patients (5 males; 15 females; age, 57.9 +/- 2.0 years; body mass index, 28.0 +/- 0.8 kg/m(2)) With AI and typical computed tomographic features of cortical adenoma, who were not affected by diabetes mellitus, hypertension, or other relevant diseases. All patients underwent anthropometric measurements and determination of basal corticotropin, cortisol, and urinary free cortisol excretion. Overnight dexamethasone test and 250-mu g corticotropin test were performed in all cases. A subclinical Cushing syndrome was found in 3 patients, whereas the others had apparently nonfunctioning masses. Plasma IL-6, adiponectin, resistin, TNF-alpha, and MCP-1 levels were higher in patients than in controls (64.4 +/- 2.8 vs 5.5 +/- 0.6 pg/mL, 13.7 +/- 1.3 vs 3.6 +/- 0.5 pg/mL, 12.5 +/- 1.9 vs 5.1 +/- 0.2 ng/mL, 27.0 +/- 1.5 vs 22.2 +/- 1.5 pg/mL, 172.5 +/- 20.0 vs 104.4 +/- 19.5 pg/mL, respectively; P < .05) and apparently not affected by the presence of visceral obesity. Plasma IL-6 levels were negatively correlated with urinary free cortisol (r = -0.461, P < .05), and TNF-alpha levels were positively correlated with cortisol after the administration of 1 mg dexamethasone (r = 0.636, P < . 01). In conclusion, patients with AI may show increased levels of adipokines (apparently not related to the presence of diabetes, hypertension, or obesity), which may be affected by the presence of the adrenal adenoma. For some adipokines, a direct production from the adrenal gland may be hypothesized even if other studies are needed to better investigate the role of adipokines in states of altered cortisol secretion. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:686 / 692
页数:7
相关论文
共 37 条
[1]   ABNORMALITIES OF ENDOCRINE FUNCTION IN PATIENTS WITH CLINICALLY SILENT ADRENAL MASSES [J].
AMBROSI, B ;
PEVERELLI, S ;
PASSINI, E ;
RE, T ;
FERRARIO, R ;
COLOMBO, P ;
SARTORIO, A ;
FAGLIA, G .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1995, 132 (04) :422-428
[2]   Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes [J].
de Lemos, JA ;
Morrow, DA ;
Sabatine, MS ;
Murphy, SA ;
Gibson, CM ;
Antman, EM ;
McCabe, CH ;
Cannon, CP ;
Braunwald, E .
CIRCULATION, 2003, 107 (05) :690-695
[3]   Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome [J].
Fallo, F ;
Scarda, A ;
Sonino, N ;
Paoletta, A ;
Boscaro, M ;
Pagano, C ;
Federspil, G ;
Vettor, R .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 150 (03) :339-344
[4]   Monocyte chemoattractant protein 1 expression is stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytes [J].
Fasshauer, M ;
Klein, J ;
Kralisch, S ;
Klier, M ;
Lossner, U ;
Bluher, M ;
Paschke, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 317 (02) :598-604
[5]   Regulation of adipocytokines and insulin resistance [J].
Fasshauer, M ;
Paschke, R .
DIABETOLOGIA, 2003, 46 (12) :1594-1603
[6]   Novel interactions of adiponectin with the endocrine system and inflammatory parameters [J].
Fernández-Real, JM ;
López-Bermejo, A ;
Casamitjana, R ;
Ricart, W .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (06) :2714-2718
[7]   Newer diagnostic techniques and problems in Cushing's disease [J].
Findling, JW ;
Raff, H .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1999, 28 (01) :191-+
[8]   Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome [J].
Garrapa, GGM ;
Pantanetti, P ;
Arnaldi, G ;
Mantero, F ;
Faloia, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (11) :5301-5306
[9]   Diurnal and ultradian dynamics of serum adiponectin in healthy men: Comparison with leptin, circulating soluble leptin receptor, and cortisol patterns [J].
Gavrila, A ;
Peng, CK ;
Chan, JL ;
Mietus, JE ;
Goldberger, AL ;
Mantzoros, CS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (06) :2838-2843
[10]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421